Why ImmuCell Corporation’s (ICCC) Stock Is Down 8.62%
As of Friday, August 14, ImmuCell Corporation’s ICCC share price has dipped by 8.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Commentary & Analysis
Why ImmuCell Corporation’s (ICCC) Stock Is Up 6.15%
As of Thursday, July 16, ImmuCell Corporation’s ICCC share price has surged by 6.15%, which has investors questioning if this is right time to sell.Michael Rose
Why ImmuCell Corporation’s (ICCC) Stock Is Down 5.97%
As of Wednesday, July 15, ImmuCell Corporation’s ICCC share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ImmuCell Corporation’s (ICCC) Stock Is Up 6.05%
As of Tuesday, July 14, ImmuCell Corporation’s ICCC share price has surged by 6.05%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why ImmuCell Corporation’s (ICCC) Stock Is Up 6.59%
As of Thursday, July 09, ImmuCell Corporation’s ICCC share price has surged by 6.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $90.8 | $288.9 | 20% |
|
| Shares Out (Mil) | 9.2 | 54.0 | 20% |
|
| Institutional Ownership | 40.0% | 93.1% | 16% |
|
| Float (Mil) | 6.0 | 41.4 | 14% |
|
| Beta | 0.57 | 0.94 | 33% |
|
| Avg Daily Volume (000s) | 24 | 480 | 22% |
|
| Price Change (52-week) |
61.8% | 59.9% | 85% |
|
| Growth | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.5% | 14.1% | 66% |
|
| Net Income (5yr) | 0.0% | (10.1%) | 40% |
|
| EPS (5yr) | 3.3% | 15.9% | 36 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.6%) | (15.6%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $31 | $37 | 16% |
|
| Net Income (TTM) (Mil) | $1 | ($43) | 40% |
|
| EPS (TTM) | $0.087 | ($1.500) | 43% |
|
| Operating Cash Flow (TTM) (Mil) | $6 | ($31) | 36% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $2 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $96 | $190 | 21% |
|
| Valuation | ICCC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.90 | 2.84 | 64% |
|
| P/E | 133.3 | 20.0 | 95% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 40.4 | 1.1 | 99% |
|
| Ratios | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.3% | 66.9% | 50% |
|
| Net Margin | 2.6% | (74.2%) | 40% |
|
| ROA | 1.7% | (47.7%) | 53% |
|
| ROE | 2.6% | (55.0%) | 39% |
|
| Liabilities to Assets | 32.7% | 29.6% | 24% |
|
| F-Score | 7 | 3 | 82% |
|
ImmuCell Corporation did not pass any screens on 9/2/2026.
